Population Pharmacokinetic/Pharmacodynamic Modeling of Glenzocimab (ACT017) a Glycoprotein VI Inhibitor of Collagen‐Induced Platelet Aggregation

Glenzocimab (ACT017) is a humanized monoclonal antigen‐binding fragment (Fab) directed against the human platelet glycoprotein VI, a key receptor for collagen and fibrin that plays a major role in thrombus growth and stability. Glenzocimab is being developed as an antiplatelet agent to treat the acu...

Descripción completa

Detalles Bibliográficos
Autores principales: Renaud, Lionel, Lebozec, Kristell, Voors‐Pette, Christine, Dogterom, Peter, Billiald, Philippe, Jandrot Perrus, Martine, Pletan, Yannick, Machacek, Matthias
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Non Covid Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7496554/
https://www.ncbi.nlm.nih.gov/pubmed/32500636
http://dx.doi.org/10.1002/jcph.1616

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7496554/
https://www.ncbi.nlm.nih.gov/pubmed/32500636
http://dx.doi.org/10.1002/jcph.1616

Ejemplares similares